Molecular Evolution of Antifungal Drug Resistance
The fungal pathogens Candida albicans , Cryptococcus neoformans , and Aspergillus fumigatus have transitioned from a rare curiosity to a leading cause of human mortality. The management of infections caused by these organisms is intimately dependent on the efficacy of antifungal agents; however, fun...
Saved in:
Published in | Annual review of microbiology Vol. 71; no. 1; pp. 753 - 775 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
Annual Reviews
08.09.2017
Annual Reviews, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The fungal pathogens
Candida albicans
,
Cryptococcus neoformans
, and
Aspergillus fumigatus
have transitioned from a rare curiosity to a leading cause of human mortality. The management of infections caused by these organisms is intimately dependent on the efficacy of antifungal agents; however, fungi that are resistant to these treatments are regularly isolated in the clinic, impeding our ability to control infections. Given the significant impact fungal pathogens have on human health, it is imperative to understand the molecular mechanisms that govern antifungal drug resistance. This review describes our current knowledge of the mechanisms by which antifungal drug resistance evolves in experimental populations and clinical settings. We explore current antifungal treatment options and discuss promising strategies to impede the evolution of drug resistance. By tackling antifungal drug resistance as an evolutionary problem, there is potential to improve the utility of current treatments and accelerate the development of novel therapeutic strategies. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 0066-4227 1545-3251 |
DOI: | 10.1146/annurev-micro-030117-020345 |